Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Aviance Capital Partners LLC

Aviance Capital Partners LLC cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,708 shares of the specialty pharmaceutical company’s stock after selling 795 shares during the quarter. Aviance Capital Partners LLC’s holdings in Jazz Pharmaceuticals were worth $1,169,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in JAZZ. Vestal Point Capital LP acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $89,175,000. Armistice Capital LLC raised its position in Jazz Pharmaceuticals by 108.4% during the fourth quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock worth $80,150,000 after acquiring an additional 338,882 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares in the last quarter. Perpetual Ltd grew its position in shares of Jazz Pharmaceuticals by 54.0% in the first quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company’s stock valued at $57,202,000 after purchasing an additional 166,543 shares during the last quarter. Finally, Baupost Group LLC MA raised its position in shares of Jazz Pharmaceuticals by 23.7% during the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after purchasing an additional 160,000 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Barclays reduced their target price on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday, May 3rd. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Truist Financial reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Piper Sandler lifted their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $190.00.

Insider Activity

In related news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $106.47 on Tuesday. The business has a 50-day moving average of $108.89 and a two-hundred day moving average of $116.55. The firm has a market capitalization of $6.71 billion, a PE ratio of 21.95, a P/E/G ratio of 1.64 and a beta of 0.58. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. As a group, research analysts forecast that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.